[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:burkitt-lymphoma:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Burkitt Lymphoma","CD19 Gene",6,[8,16,22,29,35,41],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[26],"Phase 1","2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[26],"2026-08-26T02:19:30.857183Z","2026-05-05T02:35:31.752653Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[26],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.644184Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[26],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z"]